Bengaluru, Mar 12: Aster DM Healthcare Limited has received an overwhelming 96.68% voting approval from shareholders, along with a significant majority of minority shareholders and creditors, in favour of its proposed Scheme of Amalgamation with Quality Care India Limited (QCIL). The approval follows strong shareholder support for the share swap arrangement preceding the merger, reflecting broad-based investor confidence in the strategic transaction.
The merger is expected to be completed in the next quarter, subject to the receipt of remaining regulatory and statutory approvals from the National Company Law Tribunal (NCLT).
Commenting on the strong shareholder backing, Azad Moopen, Founder Chairman of Aster DM Healthcare, said:
“The strong support from our shareholders reflects their confidence in the strategic rationale of this merger and the long-term value it will deliver. By bringing together Aster DM Healthcare and Quality Care India, we are building a scaled, future-ready healthcare platform with the clinical depth, operational strength and governance framework required to serve millions of patients across the country.
This partnership combines Aster’s legacy of patient-centric care and physician leadership with the institutional strength and growth expertise of Blackstone. Together, we are well positioned to expand access to high-quality healthcare, invest in clinical excellence and innovation, and create one of India’s leading integrated healthcare networks.”
Upon completion, the combined entity is expected to emerge as one of the top three hospital chains in India, with a diversified presence across 9 states and 28 cities. The merged platform will operate 39 hospitals with over 10,625 beds, supported by 36,307+ employees and clinicians, serving millions of patients annually across hospitals, clinics, laboratories, and allied healthcare services.
India continues to remain Aster’s largest growth market. The merged entity plans to expand total capacity to approximately 14,710+ beds in the coming years. Of the planned 4,080+ additional beds, around 2,368 beds will be added by Aster, while the remaining expansion will be driven by QCIL.
Aster’s expansion strategy will be supported by a capital outlay of approximately ₹2,300 crore, of which ₹350 crore has already been invested in critical projects as of September 2025.
Expansion Plans Across Key Markets
The company plans to add around 2,368 beds across India through a mix of greenfield projects and selective acquisitions, strengthening its presence in key states such as Kerala and Karnataka, where it already has a strong foothold.
Key upcoming additions include two new hospitals in Bengaluru:
-
A 430-bed facility on Sarjapur Road
-
A 500-bed hospital in Yeshwanthpur
Additionally, the company will expand capacity by adding:
-
350 beds at Aster CMI Hospital
-
159 beds at Aster Whitefield Hospital
These developments will further reinforce Aster’s position among the top three healthcare providers in Bengaluru.
In Kerala, the 263-bed Aster Kasaragod Hospital became operational in October 2025. Meanwhile, the 454-bed Aster Capital Hospital in Thiruvananthapuram is currently under development. Expansion is also underway at Aster Medcity in Kochi, where 100 additional beds are being added.
Other upcoming projects include:
-
A 300-bed Women & Children’s Hospital in Hyderabad
-
A 75-bed expansion at Aster Ramesh Hospital in Ongole
